CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that Curis scientists presented a poster entitled “Design and synthesis of quinazoline derivatives as novel, potent multi-acting HDAC and receptor tyrosine kinase inhibitors for the treatment of cancer,” at the 235th American Chemical Society (ACS) National Meeting, which is being held at the Morial Convention Center in New Orleans, Louisiana, April 6-10.
